Colgate-Palmolive Company CL
Composite 54/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 31/100 — a moderate mark against it.
Quality ranks 79/100 — a strong point in its favour. Income ranks 65/100 — a moderate point in its favour. Balance-sheet strength ranks 54/100 — a slight point in its favour.
Growth ranks 31/100 — a moderate mark against it. Valuation ranks 39/100 — a slight mark against it.
What the company does Colgate-Palmolive (CL) manufactures and sells oral, personal, and home care products globally under brands such as Colgate, Palmolive, and Hill’s Pet Nutrition. Its segments include Oral, Personal and Home Care (90% of revenue) and Pet Nutrition (10%), serving traditional and e-commerce channels.
Key financials CL boasts strong profitability metrics: ROE 267%, ROA 16%, ROCE 30%, and net margins of 10%. Revenue grew 5% YoY, but EPS declined 6%. The balance sheet is healthy (debt/equity 14%, interest coverage 13x), though liquidity is tight (current ratio 1.03).
Stock health Momentum is mixed: +12% over 12 months but -5% from its 52-week high. RSI(14) sits at 54, indicating neutral momentum. The stock’s beta of 0.33 reflects low sensitivity to broader market swings.
Price vs fair value CL trades at a **discount of 6.50%** to the analyst mean target of 98.95. - Analysts highlight valuation appeal amid industry pressures (Zacks, 2026-08-12). - Recent earnings call questions focus on growth sustainability (StockStory, 2026-08-10). - Insider selling (4,170 shares) may temper sentiment (Motley Fool, 2026-08-09).
Looking forward Forward P/E (24x) and PEG (0.47) suggest reasonable valuation vs. growth. Pet Nutrition and emerging-market demand remain key drivers, offsetting margin pressures in core categories. Dividend yield is 2.3% with a 55% payout ratio.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.